RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production by unknown
Meng et al. Virology Journal 2012, 9:238
http://www.virologyj.com/content/9/1/238METHODOLOGY Open AccessRNA polymerase I-driven reverse genetics system
for enterovirus 71 and its implications for vaccine
production
Tao Meng1, Tanja K Kiener1 and Jimmy Kwang1,2*Abstract
Background: Enterovirus 71 (EV71) is a virus that causes from mild hand, foot and mouth disease (HFMD) to severe
neurological complications and deaths in infants and young children. Effective antiviral agents and vaccines against
EV71 are not available. However, Vero cell-based chemically inactivated EV71 vaccines could be developed soon
based on the success of inactivated polio vaccine. Like poliovirus, EV71 has a positive single-stranded RNA genome
of about 7400 nucleotides which contains a single open reading frame (ORF) flanked by conserved and
untranslated regions at both the 50 and 30 ends.
Results: The universal amplification of the full length genome of EV71 regardless of its genetic diversity, and the
subsequent construction of a human RNA polymerase I-driven reverse genetics (RG) system to produce pure virus
stocks in Vero cell within 10 days were described. The rescued viruses were characterized by DNA sequencing,
cytopathic effect (CPE) and indirect fluorescent assay (IFA) in comparison with the wild-type viruses. Moreover, the
rescued viruses grew to high titers and retained the same immunogenicity as the wild-type viruses.
Conclusion: We have established a simplified method to rescue RG EV71 virus from diverse clinical isolates with
detailed genetic information and to prepare virus stocks in only 10 days. This method could accelerate EV71
vaccine development.
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Enterovirus 71 (EV71) belongs to the enterovirus genus
of the picornavirus family, which also includes coxsack-
ievirus A16 (CA16), poliovirus and echovirus [1]. EV71
has a small and nonenveloped icosahedral capsid com-
prising of four structural proteins (VP1 to VP4) and sur-
rounding a genome of ~7,400 nt single stranded RNA.
The viral genome contains a single large open reading
frame (ORF) encoding a polyprotein which is subse-
quently cleaved into multiple mature proteins by virally
encoded proteases. The ORF is flanked by 50- and 30- un-
translated regions (50- and 30- UTR) which are highly
conserved and play essential roles during the viral life* Correspondence: kwang@tll.org.sg
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reproduction in any medium, provided the orcycle. There is also a short poly A tail following the 30-
UTR [2,3]. The EV71 genome mutates rapidly because
of the low fidelity of its RNA dependent RNA polymer-
ase [4,5]. Based on a phylogenetic tree of VP1 gene
sequences, EV71 is divided into three major genogroups
(denoted A, B and C), and various subgenogroups within
genogroups B (B1 to B5) and C (C1 to C5) [4-6]. Pre-
dominant subgenotypes currently circulating are B5, C1,
C4 and C5; and different genotypes of EV71 strains may
co-circulate in the same area. Additionally, intra- or
inter-genogroup recombination and positive selection
contribute to the genetic and antigenic diversity of EV71
[7,8].
EV71 is a causative agent of hand, foot and mouth dis-
ease (HFMD), most frequently affecting infants and chil-
dren below 6 years old. Infection with EV71 is usually
mild but occasionally leads to neurological manifesta-
tions ranging from aseptic meningitis to acute flaccid
paralysis and lethal brainstem encephalitis [9,10]. Largetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Asia-Pacific region since the 1990s [2,6,11]. Unfortu-
nately, no effective medications or prophylactic vaccines
are currently available for controlling EV71 infection.
Mass vaccination of formaldehyde inactivated or adapted
live attenuated EV71, grown in African green monkey
kidney (Vero) cell, would be a favorable method to con-
trol EV71 epidemics based on the successful experience
in poliovirus vaccination [12]. Therefore, the selectionFigure 1 Rescue of EV71 viruses by hPolI-driven reverse genetics (RG
(~ 7.5 Kb). RNA of wild-type EV71 strains belonging to subgenogroup A, B2
from Malaysia was extracted and amplified using two universal primers EV7
DNA ladder (Bio-rad). (B) Strategy for the construction of EV71 RG plasmid.
identical nucleotides at both 50 and 30 ends. They were joined together so
terminator (mTer) using In-Fusion cloning method. The recombinant plasm
transfection into Vero cell. (C) CPE and IFA identification of the rescued EV7
viruses were observed for CPE at 5 days after infection. The mock and pJET
signals were detected at 24 h in the tranfected cells and cells infected with
treating with guinea pig anti EV71 serum.and characterization of EV71 vaccine strains with high
growth titers and broad cross-subgenogroup virus neu-
tralizing antibody responses are urgent for vaccine de-
velopment [13].
Reverse genetics (RG) permits the use of complemen-
tary DNA (cDNA) copies of viral RNA genome to rescue
virus with detailed features of viral genetic diversity,
antigenicity and virulence. RG systems using T7 or S6
RNA polymerase to synthesize infectious RNA in vitro) system. (A) Amplification of the full-length genomic cDNA of EV71
, B4, B5, C1, C2, C4 or C5 and 5 unknown EV71 strains (#363 to #577)
1-Uni-F and EV71-Uni-R in a fast RT-PCR reaction. L represented 2log
The linear pJET-hPolI/mTer vector and EV71 cDNA amplicon had 15
that EV71 cDNA was directly flanked by hPolI promoter and murine
id produced authentic and infectious viral genomic RNA upon
1-B5 RG virus. Vero cells infected by the EV71-B5 RG or wild-type
-hPolI/mTer-EV71-B5 plasmid transfected cells did not show CPE. IFA
RG or wild-type B5 virus; while mock cells were negative after
Figure 2 Comparative study of growth of EV71-B5 RG and wild-
type (wt) viruses. (A) Growth titer (TCID50) of six rescued EV71-B5
RG viruses at different passages in Vero cells. Each column
represents the arithmetic mean value of two duplicated
experiments. (B) One-step growth curves of three selected B5 RG
viruses and the wild-type B5 in Vero cells. The cells infected at a MOI
of 1 were harvested at several time points and the virus titer
(TCID50) was determined. The data shown are the arithmetic mean
values of duplicated experiments.
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viruses, including EV71 [14,15]. In addition, RNA poly-
merase I-based RG systems which ensure the precise
and efficient transcription of viral genomes in vivo have
been described for influenza virus [16], HFMD [17] and
EV71 [18].
Here, we have developed a robust RT-PCR method for
the universal amplification of whole EV71 genome and a
novel human RNA polymerase I (hPolI)-driven RG sys-
tem for the rapid production of pure and immunogenic
stock in Vero cell. The implications of these findings are
discussed.
Results
Initially, two primers EV71-Uni-F and EV71-Uni-R were
designed to take advantage of the conserved viral RNA
termini and contain 15 extra bases at the 50 end for join-
ing with hPolI promoter and murine terminator (mTer)
during the In-Fusion reaction. The genomic RNAs of
EV71 strains of different subgenogroups (A, B2, B4, B5,
C1, C2, C4 or C5) isolated from 1970 to 2010 were effi-
ciently amplified by RT-PCR using above primers. More-
over, to help combat and study the emerging EV71
strains from Malaysia, the unknown genomes of 5
strains #363 to #577 (Figure 1A), isolated in 2010, were
amplified, sequenced and genotyped. Although all the
strains belonged to subgenogroup B5, new mutations,
especially in the VP1 gene, were discovered (data not
shown). The EV71 cDNA amplicons had a size of about
7.5 kb and were clearly visible on the agarose gels
stained with ethidium bromide (Figure 1A). The purified
cDNA amplicons were directly joined with linearized
pJET-hPolI/mTer vector during the In-Fusion cloning
reaction without any enzyme digestion (Figure 1B). Dur-
ing the PCR screening next day, more than 80% of the
colonies showed positive recombinations (data not
shown), which indicated that this method is reliable.
To determine whether RG viruses were rescued and
infectious after directly transfection of recombinant plas-
mids, both transfected and RG virus infected cells were
analyzed by CPE and IFA. Here, only EV71-B5 was pre-
sented as an example because other EV71 strains
showed a similar pattern. After the transfection of the
recombinant plasmid pJET-hPolI/mTer-EV71-B5, we did
not observed the CPE under light microscopy at the
third post transfection day because little RG viruses were
generated from EV71-B5 cDNA constructs. However,
the CPE was obvious when fresh Vero cells were infected
by rescued RG EV71-B5 from transfection (P1 infection,
Figure 1C). Furthermore, IFA results showed that trans-
fected or RG virus infected cells were positive by immu-
nostaining with guinea pig anti EV71 serum (Figure 1C).
Additionally, the viral proteins VP1 and 3D were both
detectable after the transfection and infection usingmouse monoclonal antibodies 1D9 and 4B12 (Additional
file 1). Therefore, the hPolI promoter was active and the
EV71 genomic RNA was successfully transcribed inside
Vero cell, and the rescued RG EV71-B5 viruses were in-
fectious and produced viral proteins inside cells.
To further compare the growth characteristics of the
rescued virus and wild-type virus, their growth titers at
different passages and a one-step growth curve were
studied. Six positive recombinant plasmids pJET-hPolI/
mTer-EV71-B5 were separately transfected into Vero
cells. After 3 days, 1ug of each plasmid produced around
103 TICD50 infectious viruses (Figure 2A). After the first
and second passage, the RG virus titers grew to above104
and 106 TICD50 /ml in Vero cell, respectively; and the
titer was high enough to establish a virus seed stock. At
the sixth passage, the growth titer of RG viruses was just
slightly lower than wild type viruses (Figure 2A), which
indicated the RG virus is suitable to be grown at large
scale for vaccine production. The growth kinetics of the
six RG viruses (B5-RG1 to B5-RG6) from the 5th passage
in Vero cell was examined by one-step growth curve
study. The results showed that the rescued B5-RG
viruses displayed as statistically similar titers at each
time point as the wild type B5 in Vero cell. Peak titers
Figure 3 Illustration of a streamlined scheme for rapid
production of EV71 RG viruses that could be used as vaccine
seed stocks. The illustration begins with a clinical EV71 isolate
which could be from any subgenogroup.
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type and RG viruses (Figure 2B).
To test whether the RG viruses retained the same im-
munogenicity as wild-type virus, two RG viruses B5-RG1
and B5-RG2 were randomly chosen for immunogenic
study in mice. The formalin inactivated whole EV71-B5
RG and wild type viruses with AlPO4 adjuvant were
injected into mice on day 0 and 14. Mouse immunogen-
icity studies (Table 1) revealed that two RG viruses B5-
RG1 and B5-RG2 were immunogenic and elicited good
cross-genogroup virus neutralization titers (28 for hom-
ologous B5 strain and > 24 for other heterologous EV71
strains) on day 21. In addition, the neutralization titers
elicited by RG and wild-type of EV71-B5 were statisti-
cally identical. The results indicated that the RG viruses
retained the immunogenicity of their original wild-type
virus. Hence, the pure viruses rescued by this novel
RG system have great potential advantages in vaccine
production.
Discussion
In conventional studies, the infectious clones of single-
stranded positive RNA viruses with large genome, such
as poliovirus and FMDV, were constructed by elaborate
ligation of several subgenomic clones generated from
multiple, segmented RT-PCR due to the difficulties in
long template PCR amplification [19-21]. To amplify the
full length 7.5 kb cDNA of EV71 genome, we designed a
pair of universal primers which could successfully amp-
lify all known EV71 strains in a fast PCR reaction using
high fidelity pfuUltra DNA polymerase. Because of gen-
etic diversity of EV71, the selection of restriction
enzymes for plasmid construction was laborious. In our
system, the cDNA amplicons were directly joined with
the linearized vector in the In-fusion cloning reaction.
The whole procedure could be done in only one day
(Figure 3).
In our previous paper, we described an hPolI-driven
RG system for generating infectious EV71 from synthetic
cDNA in RD cell [18]. In this study, we tried a similar
system to rescue EV71 viruses in Vero cell for vaccine
production. This RG system takes advantage of host
RNA polymerase I promoter to generate exact EV71-likeTable 1 Comparison of immunogenicity of formalin-inactivate
Antigen Log2 (titer of neutral
EV71-B2 EV71-B4 EV71-B5
B5-wt 7(0.89) 7.8(0.98) 8(0.89)
B5-RG1 7(1.26) 7.3(1.03) 7.8(0.75)
B5-RG2 7(0.89) 7.16(1.17) 8 (0.63)
PBS < 3 < 3 < 3
Cross-neutralization antibodies titers elicited in mice by RG and wt EV71-B5 viruses
different subgenogroups. The experiment was duplicated and the data represents tvRNA with precise initiation and termination inside
Vero cell. Unlike to T7 or SP6 polymerase-driven RG
systems, no extra bases were added during in vivo tran-
scription at the 50 and 30 ends of viral RNA transcripts
(Figure 1B). Those extra bases had been reported to im-
pede the rescue of some RG viruses [22,23].
Traditionally, potential EV71 vaccine strains are firstly
selected from hundreds of clinical isolates which are
usually cultured in RD cell. Candidate strains with low
virulence and high immunogenicity are then attenuated
in Vero cell which has been approved for EV71 vaccine
production [13,24]. Plaque screening and further subcul-
ture are then performed to select and purify the candi-
date strains with higher growth titers. The genomic
stability and immunogenicity of candidate strains in pas-
sages have to be maintained. The whole procedure is
time-consuming and haphazard, and contamination with
pathogens derived from the clinical samples or non-
validated cell culture systems can occur [25]. In contrast,
our hPolI-driven RG system our procedure was faster
because it excludes the chance of contamination byd RG and wild-type (wt) viruses
izing antibody) against (mean (SD)):
EV71-C1 EV71-C2 EV71-C4 EV71-C5
5.1(0.75) 5.7(0.75) 4.2(0.75) 4.7(0.82)
4.8(0.75) 5(0.63) 4.3(0.82) 4.83(0.75)
4.6(0.82) 5.2 (0.4) 4.2(0.98) 4.5(0.55)
< 3 < 3 < 3 < 3
were almost the same against homologous or heterologous EV71 strains from
he arithmetic mean value (n=6)±SD.
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identical cDNA construct in 10 days (Figure 3). Add-
itionally, this method is less haphazard because the exact
genome sequence for each clone was known from the
beginning which permits genomic comparison and en-
gineering to exclude clones carrying virulence determi-
nants or to introduce desired traits.
Conclusions
In conclusion, we have established a robust RT-PCR
method to amplify the entire genome of EV71, regardless
of its subgenogroup, with a pair of universal primers, and
used these amplicons for both high-throughput sequen-
cing and direct incorporation into a reverse-genetics
plasmid containing an hPolI promoter to rapidly produce
infectious EV71 seed stock. The whole procedure took
10 days only. Furthermore, the rescued RG viruses
retained the same immunogenicity as wild type viruses in
mouse. This RG system greatly simplifies the isolation
and selection of EV71 vaccine candidates and could ac-
celerate the development of EV71 vaccines.
Materials and methods
Cell culture and virus propagation
Human rhabdomyosarcoma (RD) cell and Vero cell were
maintained in Minimum Essential medium (MEM,
Gibco) containing 10% fetal bovine serum (FBS, iDNA)
at 37°C in the presence of 5% CO2. The EV71 strains
used in this study were EV71-A (BrCr, U22521.1), EV71-
B2 (7432/MS/87, U22522.1), EV71-B4 (HFMD41 /SIN),
EV71-B5 (NUH0083/SIN/08, FJ461781), EV71-C1
(Y90-3761, AB433864), EV71-C2 (1585-Yamagata-01,
AB177812), EV71-C4 (75-Yamagata-03, AB177813),
EV71-C5 (3437/SIN/06, GU222654), and some unknown
EV71 strains from Malaysia labeled #363, #366, #396,
#482, and #557. All EV71 wild type strains were isolated
from patients and propagated in RD cell. All reverse gen-
etics viruses were rescued in Vero cells.
EV71 genomic cDNA amplification
Viral RNA was extracted from culture supernatant using
RNeasy mini kit (Qiagen). The reverse transcription reac-
tion was performed for 1 hour at 42°C with RevertAid
First Strand cDNA Synthesis Kit (Fermentas) using viral
RNA as the template and oligo(dT)18 as primer. The full-
length genomic cDNAs of EV71 were amplified using
PfuUltra II Hotstart PCR Master Mix (Agilent Technolo-
gies, Inc) and EV71 specific universal primers EV71-Uni-F
(50-GGCCGCCGGGTTATTTTAAAACAGCCTGTGGG
TTG) and EV71-Uni-R (50-CCGAAGTTGGGGGGG
TTTTTTTTTTTTTTTTTTTTTTTTTTGCTATTCYG
GTTATAAC). The reaction parameters were as fol-
lows: an initiation step at 94°C for 2 min, followed by
40 cycles (94°C for 15 sec, 52°C for 20 sec and 72°Cfor 4 min) and a final extension step at 72°C for 5
min. The amplicons were analyzed by gel electrophor-
esis and purified using QIAquick gel Purification Kit
(Qiagen).
Construction of recombinant plasmids for RG EV71
The human RNA polymerase I (hPolI) promoter and
murine terminator cassette sequence were amplified
from sap/pol vector and then inserted into pJET1.2
vector as described previously [18]. The plasmid pJET-
hPolI/mTer was linearized by PCR using primers
pJET-HPol1mTer-f (50-CCCCCCCAACTTCGGAGGTC)
and pJET-hPol1mTer-r (50- AATAACCCGGCGGCC
CAAAATG). The EV71 genomic cDNA amplicons were
joined with linearized pJET-hPolI/mTer using In-Fusion
HD cloning Kit (Agilent Technologies, Inc). 5 μl of the
cloning reaction was transformed into 100 μl of compe-
tent XL1-Blue E. coli by heat shock. The recombinant
plasmids were selected by PCR screening with primers
pJET-f (50-CGACTCACTATAGGGAGAGCGGC) and
EV71-VP1-r (50-GCYCCRTATTC AAGRTCTTTCTC),
and their correctness and genotypes were confirmed
by DNA sequencing and phylogenetic tree analysis,
respectively.
Transfection and infection
A mixture of 1 μg of each recombinant plasmid and 2.5
μl Lipofectamine 2000 reagent (Invitrogen) was trans-
fected into 5x105 Vero cells in 2 ml medium in 6-well
plates. The transfected cells were lysed after 3 days by 3
freeze-thaw cycles and the supernatant containing
viruses was collected for further passage. The rescued
viruses were harvested after 4 days and their titers were
determined as 50% tissue culture infective dose (TCID50)
according to cytopathic effect (CPE) in Vero cell using
the Reed and Muench formula.
One-step growth curve of rescued viruses
The growth kinetics of rescued viruses was deter-
mined in subconfluent Vero cell culture in 1 ml
medium in 24-well plates. The cells were incubated
with rescued viruses at a multiplicity of infection
(MOI) of 1 for 1 h at 37°C, and then washed with
PBS 3 times and cultured in MEM with 2% FBS. The
infected cells were frozen at day 2, 3, 4, 5, 6 and 7
post-infection and stored at -80°C. After 3 freeze-
thaw cycles, the virus concentrations were titrated by
TCID50 assay.
Indirect immunofluorescence assay (IFA)
Vero cells transfected with the recombinant plasmids or
infected with rescued RG virus were grown in 96-well
plates. The cells were fixed with 4% PFA after 24 h and
incubated with guinea pig anti EV71 serum (produced in
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were washed and incubated with fluorescein isothiocyan-
ate (FITC)-labeled goat anti-guinea pig IgG (Dako)
diluted 1:200 for another 30 min. Finally, the cells were
rinsed with PBS and visualized under a fluorescent
microscope (Olympus).Immunogenicity of RG viruses in mouse
The rescued and wild type viruses in Vero cell were har-
vested at 5th day post-infection and purified by ultracen-
trifugation as described previously [18]. The purified
viruses were then inactivated with 0.2% formalin (v/v) at
37°C for 3 days and stored at 4°C, and the amount of
viral protein was determined using Bradford assay (Bio-
Rad Laboratories, USA). For immunization, groups of 6
female BALB/c mice (6 to 8-week old) were each intra-
peritoneally immunized with 25 μg inactivated viruses in
200 μl of 0.1 M aluminum phosphate (Sigma) or PBS as
a negative control. The mice were boosted with the same
dose 2 weeks after priming. The sera were then collected
one week after the boost and the presence of neutraliz-
ing antibodies against EV71 was assayed by an in vitro
microneutralization assay [18]. Briefly, 25 μl of serial
twofold dilutions of heat inactivated serum samples were
mixed with 25 μl of 100 TCID50 of virus, and the
neutralization antibody titer was determined as the high-
est dilution of serum that protected 50% of Vero cell
cultures.
All animal experiments were carried out in accordance
with the Guides for Animal Experiments of the National
Institute of Infectious Diseases (NIID), and experimental
protocols were reviewed and approved by the Institu-
tional Animal Care and Use Committee of the Temasek
Life Sciences Laboratory, Singapore (Project Approval
no. TLL-11-002).Additional file
Additional file 1: (C) IFA identification of the rescued EV71-B5 RG
viruses. The viral proteins were detected with mouse monoclonal
antibodies 1D9 and 4B12 which were raised against VP1 and 3D of EV71,
respectively. The pJET-hPolI/mTer-EV71-B5 plasmid transfected cells and
RG EV71-B5 or wild-type B5 infected cells showed positive IFA signals at
24 h; while mock cells were negative.Abbreviations
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